Host-related concordance of TAC/SARIFA in colorectal double and triple carcinomas suggests patient-specific metabolic reprogramming
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Introduction
TAC/SARIFA has been introduced as a new robust and easy to evaluate biomarker in several cancer entities including colorectal cancer. It is defined by a direct contact of at least five tumour cells with one adipocyte and is believed to indicate metabolic reprogramming associated with adverse outcome. However, the mechanism that leads to TAC/SARIFA-positivity is unclear, yet. To investigate whether there is an individual’s component we conducted a study on double and triple cancer establishing a within-patient-design.
Methods
We retrospectively analysed a total number of 135 cases with 276 col-orectal cancers from two academic medical centres. The TAC/SARIFA status was evaluated as well as the basic histopathological factors. The median follow-up time was 120 months.
Results
Cases with any TAC/SARIFA-positive tumours showed a significant reduced overall survival (62 v s. 88 months; p = 0 .011). Analysing the entire cohort the rates of concordant and discordant cases followed a random distribution. However, restriction to synchronous pT3/4-cases revealed a significant (p = 0.016) deviation from a random distribution.
Conclusion
This study reveals significant concordance of TAC/SARIFA status in synchronous locally advanced colorectal double/triple carcinomas, supporting the concept that tumour–adipocyte interaction reflects a host-related microenvironmental condition linked to metabolic reprogramming rather than a purely tumour-intrinsic event.
